Efficacy and Safety of Seated Baduanjin Exercise for Postoperative Osteoporotic Vertebral Compression Fractures After Vertebroplasty: A Protocol for Systematic Review and Meta-Analysis
Date Submitted: Apr 1, 2026
Open Peer Review Period: Apr 2, 2026 - May 28, 2026
Background: Osteoporotic vertebral fractures are a leading cause of pain, disability, and reduced quality of life in the elderly population. Although vertebroplasty is widely used to relieve pain and stabilize fractures, postoperative rehabilitation remains suboptimal, with limited functional recovery. Seated Baduanjin, a modified form of traditional Baduanjin exercise tailored for frail elderly patients, has been successfully applied in the rehabilitation of knee osteoarthritis, cervical spondylosis, and sarcopenia. However, its application in patients after vertebroplasty has not yet been systematically synthesized. Objective: This systematic review and meta-analysis aims to evaluate the efficacy and safety of seated Baduanjin exercise compared with usual care in terms of pain, physical function, and quality of life among elderly patients with osteoporotic vertebral fractures following vertebroplasty. Methods: This protocol has been registered in PROSPERO (CRD420261344980). We will search PubMed, Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP Database from inception to July 2026, with no language or date restrictions. Only randomized controlled trials evaluating seated Baduanjin in elderly patients (aged ≥60 years) after vertebroplasty will be included. Two reviewers will independently screen the literature, extract data, assess the risk of bias using the Cochrane RoB 2.0 tool, and evaluate the quality of evidence using the GRADE system. The primary outcome is pain intensity. Secondary outcomes include physical function, quality of life, and balance function. Meta-analysis will be performed using RevMan 5.4. Heterogeneity will be assessed using the I² statistic and Cochran’s Q test: a fixed-effects model will be used when I² < 50% and P ≥ 0.1; if I² ≥ 50% or P < 0.1, subgroup analyses will be conducted. If heterogeneity persists, sensitivity analyses or exploratory subgroup analyses will be performed. Should the heterogeneity remain unexplained, a random-effects model will be adopted, and the GRADE evidence level will be downgraded. Results: As of January 2026, the preliminary screening of titles and abstracts for 241 studies has been completed. Full-text screening is expected to be finalized by May 2026, and data analysis is planned for completion by August 2026. Approximately two-thirds of the relevant studies have been published since 2020. In terms of geographic distribution, the study samples are highly concentrated in Asia. The results will be comprehensively presented around the core outcomes: the primary outcome will be presented as changes in the Visual Analogue Scale (VAS). Secondary outcomes will be assessed using physical function measures such as the Oswestry Disability Index and quality of life scales such as the SF-36 and EQ-5D. The pooled effect sizes with 95% confidence intervals for the corresponding outcome measures will be reported. Additionally, the incidence of adverse events will be statistically analyzed. Conclusions: If the findings of this study confirm the efficacy and safety of seated Baduanjin exercise, it may provide a viable approach for non-pharmacological rehabilitation in elderly patients following vertebroplasty. However, some studies may have a risk of bias, such as insufficient standardization of intervention protocols and difficulty in implementing blinding. Due to variations in intervention protocols, outcome measures, and patient cultural backgrounds, substantial heterogeneity is anticipated. Moreover, the limited number of available original randomized controlled trials and the high geographic concentration of the study samples may restrict the generalizability of the conclusions. Future research should focus on optimizing intervention protocols and supplementing the evidence with high-quality, multicenter, large-sample randomized controlled trials to enhance the reliability of the findings. PROSPERO registration number: CRD 420261344980 Clinical Trial: This systematic review protocol was developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-P) guidelines. It has been registered on the International Prospective Register of Systematic Reviews (PROSPERO) platform (CRD420261344980). Any methodological changes during the research process will be recorded and updated in the PROSPERO record.